-
公开(公告)号：US20240252471A1
公开(公告)日：2024-08-01
申请号：US18526686
申请日：2023-12-01
Applicant: BioXcel Therapeutics, Inc.
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61K9/00 , A61K47/38 , A61P25/18 , A61P25/20
CPC classification number: A61K31/4174 , A61K9/006 , A61K47/38 , A61P25/18 , A61P25/20
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20240024288A1
公开(公告)日：2024-01-25
申请号：US17628021
申请日：2020-07-17
Applicant: BioXcel Therapeutics, Inc. , ARx, LLC
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Scott David BARNHART , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61P25/18 , A61K9/00 , A61P25/20 , A61P25/36
CPC classification number: A61K31/4174 , A61P25/18 , A61K9/006 , A61P25/20 , A61P25/36
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20230338339A1
公开(公告)日：2023-10-26
申请号：US18216890
申请日：2023-06-30
Applicant: BioXcel Therapeutics, Inc.
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61P25/18 , A61K9/00 , A61K9/06 , A61K9/20 , A61K9/70 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61K47/44
CPC classification number: A61K31/4174 , A61P25/18 , A61K9/006 , A61K9/06 , A61K9/2013 , A61K9/2018 , A61K9/7007 , A61K9/7015 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61K47/44
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20230118091A1
公开(公告)日：2023-04-20
申请号：US17993422
申请日：2022-11-23
Applicant: BioXcel Therapeutics, Inc. , ARx, LLC
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Scott David BARNHART , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61K9/00 , A61K9/70 , A61P25/18 , A61K47/38 , A61K47/10 , A61K47/26 , A61K47/44 , A61K47/34 , A61K9/20 , A61K9/06
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20200000717A1
公开(公告)日：2020-01-02
申请号：US16453679
申请日：2019-06-26
Applicant: BioXcel Therapeutics, Inc. , ARx, LLC
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Scott David BARNHART
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
-
Patent Agency Ranking
公开(公告)号：US20240245650A1
公开(公告)日：2024-07-25
申请号：US18176296
申请日：2023-02-28
Applicant: BioXcel Therapeutics, Inc.
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61K9/00 , A61K47/38 , A61P25/18 , A61P25/20
CPC classification number: A61K31/4174 , A61K9/006 , A61K47/38 , A61P25/18 , A61P25/20
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20240173299A1
公开(公告)日：2024-05-30
申请号：US18430003
申请日：2024-02-01
Applicant: BioXcel Therapeutics, Inc.
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Lavanya RAJACHANDRAN , Robert RISINGER
IPC: A61K31/4174 , A61K9/00 , A61K9/06 , A61K9/20 , A61K9/70 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61K47/44 , A61P25/18 , A61P25/20 , A61P25/36
CPC classification number: A61K31/4174 , A61K9/006 , A61K9/06 , A61K9/2013 , A61K9/2018 , A61K9/7007 , A61K9/7015 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61K47/44 , A61P25/18 , A61P25/20 , A61P25/36
Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
-
公开(公告)号：US20240139169A1
公开(公告)日：2024-05-02
申请号：US18278786
申请日：2022-02-25
Applicant: BioXcel Therapeutics, Inc.
Inventor： Michael DE VIVO , Friso POSTMA , David Christian HANLEY , Vasukumar KAKUMANU , Subhendu SETH , Dinesh Kumar DHULL
IPC: A61K31/444 , A61K9/00 , A61K31/4174 , A61P25/18
CPC classification number: A61K31/444 , A61K9/0056 , A61K31/4174 , A61P25/18
Abstract: The present disclosure relates to the treatment of agitation caused by noradrenergic hyperarousal in an agitated subject. The present disclosure provides oromucosal dosage forms comprising effective amounts of latrepirdine either alone or in combination with dexmedetomidine or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers and/excipients. Methods of their use are also provided. The present disclosure also provides a method of treating depression by administering oromucosally a therapeutically effective amount of dexmedetomidine alone or in combination with latrepirdine.
-
公开(公告)号：US20230390190A1
公开(公告)日：2023-12-07
申请号：US18448754
申请日：2023-08-11
Applicant: BioXcel Therapeutics, Inc. , ARx, LLC
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Scott David BARNHART
CPC classification number: A61K9/0056 , A61K31/4174 , A61P25/22 , A61K47/38 , A61K47/34 , A61K9/7007
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
-
公开(公告)号：US20200345635A1
公开(公告)日：2020-11-05
申请号：US16931630
申请日：2020-07-17
Applicant: BioXcel Therapeutics, Inc. , ARx, LLC
Inventor： Vasukumar KAKUMANU , David Christian HANLEY , Frank YOCCA , Chetan Dalpatbhai LATHIA , Scott David BARNHART
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.014 seconds)
